查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198706

子宮肌瘤治療市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Uterine Fibroids Treatment Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

子宮肌瘤治療市場預計在預測期內（2022 年至 2027 年）以 4.5% 的複合年增長率增長。

冠狀病毒大流行給全球帶來了重大變化，尤其是在醫療保健系統方面。 由於 COVID-19 大流行，所有擇期手術都已取消。 子宮肌瘤患者的風險與嚴重肢體缺血患者的風險不同，但在某些情況下，他們的生活質量會受到不利影響。 因此，減少病毒交叉傳播的選擇性治療或準備醫院以幫助受感染患者的機會有限，使婦女感到不適和無效的臨時治療。 結果，為減少病毒交叉感染或準備醫院結構以幫助感染患者而進行的選擇性治療受到限制，使婦女感到不舒服或無效的臨時治療。我必須應對這種治療。

子宮肌瘤的患病率在世界範圍內很高，越來越多的患者偏好微創治療和採用技術先進的技術將推動市場發展。 月經過多、盆腔疼痛、不孕、尿頻都是子宮肌瘤的症狀。 子宮肌瘤是在子宮內生長的平滑肌細胞的良性腫瘤。 病因不明，但危險因素包括種族、年齡、遺傳易感性、絕經前狀態、高血壓、超重和飲食。 根據《當代婦產科》2022年2月發表的文章《縱觀子宮肌瘤現狀》，預計到50歲時，超過70%的女性會患上子宮肌瘤。

此外，患者對微創和無創子宮肌瘤手術的偏好預計將推動市場發展。 這些手術越來越受歡迎，因為較小的切口可以減少術後疼痛並加快康復速度。 幾家領先的公司正在投資研發，以將新的微創和無創手術設備推向市場。 醫生經常推薦的一種非切口手術是 MRgFUS（MR 引導聚焦超聲）來治療肌瘤。 在這種治療中，超聲波束用於加熱和去除子宮腔內的特定組織。 作為一種非侵入性治療，副作用很少，患者可以在幾天內恢復正常活動。 與開放手術相比，它痛苦小、效果好、感染風險小、恢復快。

此外，作為對未滿足需求的回應，還提到了擴大非婦科醫生對子宮肌瘤的認識和教育，以及通過共同決策促進對患者的個體化治療。 例如，2021 年 11 月，專門從事 AUB 治療的女性健康公司 Minerva Surgical 宣布推出針對女性的全新消費者教育體驗，www.aubandme.com。 此外，研究新型非激素藥物療法可能會帶來不影響生殖功能的先進肌瘤治療方案。 例如，維生素 D 的上調可以保護肌瘤的生長，同時不會對卵巢功能產生不利影響。 此外，Bayer 正在投資子宮肌瘤，作為其臨床開發計劃的一部分。

因此，先進產品的可用性、手術技術以及各種市場參與者的舉措都有助於整個市場的增長。

子宮肌瘤治療市場趨勢

在子宮肌瘤治療市場，子宮切除領域有望佔據主要市場份額

COVID-19 的全球影響仍在繼續，因為所有國家/地區的醫院都在減少選擇性和非緊急病例，以便他們可以將人員和資源分配到其他地方。 根據 2021 年發表的文章“COVID-19 大流行時代的婦科腹腔鏡手術”。 一項前瞻性研究”，美國婦產科醫師和腹腔鏡醫師協會 (AAGL)、美國婦產科醫師學會 (ACOG) 和其他機構發表聯合聲明，呼籲結束擇期手術，將重點轉移到急診和癌症上手術。我建議。

子宮切除手術數量的增加是市場增長的主要驅動力之一。 此外，這種方法是最流行和最有效的永久性肌瘤治療方法。 因此，該類別將隨著相關手術數量的增加而增長。 根據美國疾病控制與預防中心 (CDC) 的數據，美國每年大約進行 600,000 例子宮切除術，正如 Verywell Health 於 2020 年 11 月發布的“美國的子宮切除術”。 根據美國婦產科學院的數據，大約三分之一的女性將在 60 歲時進行子宮切除術。

如果月經出血嚴重，切除是一種常見的手術治療方法。 在這種微創手術中，子宮內膜通過手術切除。 子宮內膜消融不需要切口，可以在醫生辦公室進行，無需全身麻醉。 此外，子宮內膜切除術後也有可能懷孕。 因此，消融手術帶來的好處預計將推動該領域的發展。

北美佔據了很大的市場份額，預計在預測期內也會如此。

COVID-19 大流行對婦科手術產生了重大影響。 美國外科醫師學會提議推遲 2020 年 3 月進行的所有非必要侵入性手術。 根據 2021 年 12 月的一篇研究論文“大型學術醫院系統對 COVID-19 反應和對婦科手術的影響的分析”，2019 年進行了 1,545 例婦科手術，而 2020 年為 1,545 例。為 942 例，表明減少了39.0%。 子宮切除術是2020年最常見的手術，子宮內膜異位症和子宮肌瘤的手術數量下降最多。 在大流行的高峰期，許多患者在尋求婦科手術治療方面出現了明顯的延誤。

該地區完善的醫療保健設施、強有力的政府舉措以及與子宮切除術相關的手術和醫院就診的增加正在推動北美市場的發展。 此外，Medtronic、Stryker 和 CooperSurgical, Inc. 等主要參與者的存在以及技術改進產品的可用性都有助於該地區的市場增長。 此外，該地區醫療技術的可及性和強大的分銷渠道也促進了肌瘤治療設備在該地區的採用。

各國政府和商業組織正在通過各種舉措提高人們對早期發現和治療子宮肌瘤的認識。 例如，在美國，七月被指定為“肌瘤宣傳月”。 近年來，提高對子宮肌瘤認識的努力有所增加。 White Dress Project、HealthyWomen.org、Fibroids Project 和 Center for Innovative GYN Care 都是眾所周知的項目。 White Dress Project 旨在通過籌集研究資金和教授女性基本知識來提高人們對子宮肌瘤的認識。 該運動鼓勵和支持女性參與並分享她們的故事。 此外，Fibroids Project 是一個在線社區和網站，致力於幫助女性擺脫肌瘤的困擾。 它旨在讓女性和醫療保健專業人員了解當前的研究、舉措和治療。 女性對子宮肌瘤治療和活動意識的提高預計將推動市場增長。

子宮肌瘤治療市場競爭者分析

肌瘤治療市場分散且競爭激烈，由幾家主要參與者組成。 市場上的一些參與者是 Myovant Sciences GmbH；Gynesonics、Boston Scientific Corporation、INSIGHTEC、Hologic, Inc、Karl Storz Gmbh、Minerva Surgical, Inc、Pfizer, Inc、Abbvie, Inc 和 ObsEva。 市場參與者正在採取各種戰略，如合併、收購和新產品開發，以保持競爭力。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 技術進步
    • 子宮肌瘤患病率增加
  • 市場製約因素
    • 與粉碎器相關的並發症
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 按類型
    • 漿膜下纖維瘤
    • 硬膜內纖維瘤
    • 黏膜下纖維瘤
    • 閉塞性纖維瘤
  • 按治療方法
    • 藥物治療
      • 黃體酮製劑
      • 左炔諾孕酮
      • 其他
    • 手術方法
      • 子宮切除術
      • 子宮肌瘤摘除術
      • 肌溶解
      • 其他
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Myovant Sciences GmbH
    • Gynesonics
    • Medtronic
    • Boston Scientific Corporation
    • INSIGHTEC
    • Hologic, Inc.
    • Karl Storz Gmbh
    • Minerva Surgical, Inc.
    • Pfizer, Inc.
    • Abbvie, Inc.
    • ObsEva

第七章市場機會與未來趨勢

簡介目錄
Product Code: 90589

The Uterine Fibroids Treatment Market is projected to register a CAGR of 4.5% during the forecast period (2022-2027).

The coronavirus pandemic has caused major changes worldwide, especially in healthcare systems. The COVID-19 pandemic resulted in the cancellation of all elective procedures. While patients with uterine fibroids are not at risk in the same way as Critical Limb Ischemia patients are, their quality of life has been adversely impaired in some cases. As a result, restrictions on access to elective therapies, imposed either to decrease virus cross-transmission or to prepare the hospital structure to aid infected patients, have forced women to live with discomfort and ineffective temporary treatments. As a result, restrictions on access to elective therapies, imposed either to decrease virus cross-transmission or to prepare the hospital structure to aid infected patients, have forced women to live with discomfort and ineffective temporary treatments.

The market is likely to be driven by the high prevalence of uterine fibroids among women worldwide, increased patient preference for less invasive procedures, and the adoption of technologically sophisticated technologies. Excessive menstrual flow, pelvic pain, infertility, and frequent urination are all symptoms of uterine fibroid (UF), a benign tumor of the smooth muscle cells that grow in the uterus. Even though the etiology is unknown, race, age, genetic susceptibility, premenopausal status, hypertension, overweight, and diet are all risk factors. Per the article published by Contemporary OB/GYN in February 2022 on "A Look At the Current State of Uterine Fibroid Care," over 70% of women are estimated to develop uterine fibroids by age 50.

Furthermore, the market is predicted to develop due to patients' preference for minimally invasive and non-invasive fibroids operations. Smaller incisions reduce post-operative pain and speed recovery, resulting in the widespread use of these procedures. Several major firms are investing in R&D to bring new minimally invasive and non-invasive surgical devices to market. One of the incision-less techniques physicians commonly suggest is MR-guided Focused Ultrasound (MRgFUS) for treating uterine fibroids. The gadget emits ultrasonic beams, which heat and remove specific tissue from the uterine cavity during this treatment. As this is a non-invasive procedure, there are little to no side effects, and patients can resume normal activities within a few days. As a result of the increased demand for such operations due to their little pain, efficacy, low risk of infection, and quick recovery compared to open surgeries, the market for uterine fibroids treatment devices is expected to rise.

Expanding uterine fibroids awareness and education beyond gynecologic professionals and promoting individualized patient treatment through collaborative decision-making were also flagged as ways to address unmet needs. For example, in November 2021, Minerva Surgical, Inc. (a women's health company specializing in treating AUB) announced the introduction of www.aubandme.com, a new consumer education experience for women. Furthermore, investigating novel non-hormonal medical therapy could lead to advanced fibroids treatment options that do not affect fertility. Upregulation of vitamin D, for example, could protect against fibroid growth while having no harmful influence on ovarian function. Furthermore, Bayer invests in uterine fibroids as part of its clinical development program.

Hence, the availability of advanced products, surgical techniques, and initiatives by various market players contribute to the overall market growth.

Uterine Fibroids Treatment Market Trends

The Hysterectomy Segment is Expected to Hold a Major Market Share in the Uterine Fibroids Treatment Market

The worldwide impact of COVID-19 continues to be felt as hospitals in all countries reduce elective and non-urgent cases to allow staffing and resources to be deployed elsewhere. As per the article published in 2021 on "Gynecological Laparoscopic Surgeries in the Era of COVID-19 Pandemic: A Prospective Study", A joint statement issued by the American Association of Gynecologic Laparoscopists (AAGL), American College of Obstetricians & Gynaecologists (ACOG), and other organizations advised the suspension of elective surgery, shifting the focus to emergency and cancer surgery.

The rising number of hysterectomy surgical procedures is one of the main drivers of market growth. Furthermore, this method is the most popular and well-proven permanent treatment for uterine fibroids. As a result, the category will likely grow as the number of related surgeries increases. As per the article published in November 2020 on "Hysterectomy in the United States", by Verywell Health, according to the Centers for Disease Control and Prevention (CDC), about 600,000 hysterectomies are performed in the United States each year. According to the American College of Obstetricians and Gynecologists, around a third of all women will have a hysterectomy by age 60.

For severe menstrual bleeding, ablation procedures are a frequent surgical treatment. The endometrial lining of the uterus is surgically abated in this minimally invasive procedure. Endometrial ablation requires no incisions and can be performed in the doctor's office without general anesthesia. Furthermore, after the endometrial ablation operation, pregnancy is conceivable. As a result, the advantages afforded by ablation procedures are projected to propel the segment forward.

North America is Expected to Hold a significant share in the market and is expected to do the Same in the Forecast Period.

The pandemic of COVID-19 has a significant impact on gynecologic surgery. The American College of Surgeons suggested delaying all non-essential invasive surgeries in March 2020. According to a December 2021 study article titled "Analysis of COVID-19 Response and Impact on Gynecologic Surgery at a Large Academic Hospital System," 1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline. The most common procedure in 2020 was a hysterectomy, whereas surgery for endometriosis and uterine fibroids saw the greatest decline in volume. Many patients had significant delays in receiving gynecologic surgical care during the peak pandemic.

The presence of well-established healthcare facilities in the region increased government initiatives, and an increase in hysterectomy-related surgical procedures/hospital visits are all driving the market in North America. Furthermore, the presence of major important companies like Medtronic, Stryker, and CooperSurgical, Inc. and the availability of technologically improved goods all contribute to the region's market growth. Furthermore, the region's adoption of uterine fibroids treatment devices is fueled by the region's easy access to healthcare technologies and strong distribution channels.

Various governments and commercial groups are working to raise awareness of early fibroids detection and treatment through various efforts. In the United States, for example, July is designated as "Fibroids Awareness Month." In recent years, more initiatives have raised awareness about uterine fibroids. The White Dress Project, HealthyWomen.org, Fibroids Project, and Center for Innovative GYN Care are just a few famous programs. The White Dress Project aims to raise awareness about fibroids by generating funding for research and educating women on the basics. This initiative encourages and supports women to join and share their stories. In addition, the Fibroids Project is an online community and website dedicated to assisting women in becoming fibroids-free. They aim to provide information about current research, initiatives, and procedures to both women and medical professionals. Growing awareness among women about uterine fibroids treatment and activities is expected to promote market growth.

Uterine Fibroids Treatment Market Competitor Analysis

The uterine fibroids treatment market is fragmented and competitive and consists of several major players. Some players operating in the market are Myovant Sciences GmbH; Gynesonics, Boston Scientific Corporation, INSIGHTEC, Hologic, Inc., Karl Storz Gmbh, Minerva Surgical, Inc., Pfizer, Inc., Abbvie, Inc., and ObsEva. Market players are adopting various strategies such as mergers, acquisitions, and new product developments to remain competitive.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements
    • 4.2.2 Growing Prevalence of Uterine Fibroids
  • 4.3 Market Restraints
    • 4.3.1 Complications Associated with Morcellators
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Subserosal Fibroids
    • 5.1.2 Intramural Fibroids
    • 5.1.3 Submucosal Fibroids
    • 5.1.4 Pedunculated Fibroids
  • 5.2 By Treatment
    • 5.2.1 Drugs
      • 5.2.1.1 Progesterone
      • 5.2.1.2 Levonorgestrel
      • 5.2.1.3 Others
    • 5.2.2 Surgical Techniques
      • 5.2.2.1 Hysterectomy
      • 5.2.2.2 Myomectomy
      • 5.2.2.3 Myolysis
      • 5.2.2.4 Others
  • 5.3 By End-user
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Myovant Sciences GmbH
    • 6.1.2 Gynesonics
    • 6.1.3 Medtronic
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 INSIGHTEC
    • 6.1.6 Hologic, Inc.
    • 6.1.7 Karl Storz Gmbh
    • 6.1.8 Minerva Surgical, Inc.
    • 6.1.9 Pfizer, Inc.
    • 6.1.10 Abbvie, Inc.
    • 6.1.11 ObsEva

7 MARKET OPPORTUNITIES AND FUTURE TRENDS